(IN BRIEF) EQT Life Sciences has co-led a €51 million Series B financing in Exciva to support a Phase 2 clinical trial of Deraphan, a novel therapy for agitation associated with Alzheimer’s disease. The round, led through the LSP Dementia … Read the full press release
Posted in Healthcare, Investment, Pharma & Biotech, Sweden
Tagged agitation, Alzheimer’s disease, Andera Partners, dementia care, Deraphan, EQT Life Sciences, Exciva, Exciva Raises €51 Million Series B to Support Phase 2 Trial for Alzheimer’s Agitation Treatment, Fountain Healthcare Partners, Gimv, Juliette Lee, LBBW, LifeArc, LSP Dementia Fund, neuropsychiatric symptoms, neuroscience therapeutics, Phase 2 clinical trial, Philip Scheltens, Series B financing
(IN BRIEF) EQT Life Sciences has led a Series A investment in Mosanna Therapeutics to advance its lead drug candidate, MOS118—a nasal spray designed to treat obstructive sleep apnea—into Phase 2 trials. Co-investors include Pivotal bioVenture Partners, Forbion, Norwest, and … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Sweden, Switzerland, Technology
Tagged airway reflex restoration, Basel, biotech funding, Daniela Begolo, David Weber, EQT Life Sciences, Forbion, Forty51 Ventures, HTGF, MOS118, Mosanna Therapeutics, nasal spray therapy, neurological treatment, non-invasive sleep apnea therapy, Norwest, obstructive sleep apnea, OSA treatment, partnership, Phase 2 clinical trial, Pivotal bioVenture Partners, Redwood City, Supermoon Capital, sustainability
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?